Percutaneous Thermal Ablation with Ultrasound Guidance. Fusion Imaging Guidance to Improve Conspicuity of Liver Metastasis
- 245 Downloads
To assess whether fusion imaging-guided percutaneous microwave ablation (MWA) can improve visibility and targeting of liver metastasis that were deemed inconspicuous on ultrasound (US).
Materials and Methods
MWA of liver metastasis not judged conspicuous enough on US was performed under CT/US fusion imaging guidance. The conspicuity before and after the fusion imaging was graded on a five-point scale, and significance was assessed by Wilcoxon test. Technical success, procedure time, and procedure-related complications were evaluated.
A total of 35 patients with 40 liver metastases (mean size 1.3 ± 0.4 cm) were enrolled. Image fusion improved conspicuity sufficiently to allow fusion-targeted MWA in 33 patients. The time required for image fusion processing and tumors’ identification averaged 10 ± 2.1 min (range 5–14). Initial conspicuity on US by inclusion criteria was 1.2 ± 0.4 (range 0–2), while conspicuity after localization on fusion imaging was 3.5 ± 1 (range 1–5, p < 0.001). Technical success rate was 83% (33/40) in intention-to-treat analysis and 100% in analysis of treated tumors. There were no major procedure-related complications.
Fusion imaging broadens the scope of US-guided MWA to metastasis lacking adequate conspicuity on conventional US. Fusion imaging is an effective tool to increase the conspicuity of liver metastases that were initially deemed non visualizable on conventional US imaging.
KeywordsFusion imaging Liver metastases Thermal ablation
Compliance with Ethical Standards
Conflicts of interest
- 3.Lee MW, Kim YJ, Park HS, et al. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR. 2010;194:394–400Google Scholar
- 4.Di Mauro E, Solbiati M, De Beni S, Forzoni L, D’Onofrio S, Solbiati L. Virtual navigator real-time ultrasound fusion imaging with positron emission tomography for liver interventions. In: Conference proceedings of IEEE Engineering in Medicine and Biology Society, 2013, pp 1406–1409.Google Scholar
- 5.Venkatesan AM, Kadoury S, Abi-Jaoudeh N, Levy EB, Maass-Moreno R, Krücker J, Dalal S, Xu S, Glossop N, Wood BJ. Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Radiology. 2011;260(3):848–56.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Wood BJ, Zhang H, Durrani A, Glossop N, Ranjan S, Lindisch D, Levy E, Banovac F, Borgert J, Krueger S, Kruecker J, Viswanathan A, Cleary K. Navigation with electromagnetic tracking for interventional radiology procedures: a feasibility study. J Vasc Interv Radiol. 2005;16(4):493–505.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Wood BJ, Locklin JK, Viswanathan A, Kruecker J, Haemmerich D, Cebral J, Sofer A, Cheng R, McCreedy E, Cleary K, McAuliffe MJ, Glossop N, Yanof J. Technologies for guidance of radiofrequency ablation in the multimodality interventional suite of the future. J Vasc Interv Radiol. 2007;18(1 Pt 1):9–24.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Minami T, Minami Y, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Inoue T, Hagiwara S, Ueshima K, Nishida N, Kudo M. Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging. Oncology. 2014;2014(87 Suppl 1):55–62.CrossRefGoogle Scholar
- 15.Nakai M, Sato M, Sahara S, Takasaka I, Kawai N, Minamiguchi H, Tanihata H, Kimura M, Takeuchi N. Radiofrequency ablation assisted by real-time virtual sonography and CT for hepatocellular carcinoma undetectable by conventional sonography. Cardiovasc Interv Radiol. 2009;32(1):62–9.CrossRefGoogle Scholar
- 18.Hakime A, Deschamps F, De Carvalho EG, Teriitehau C, Auperin A, De Baere T. Clinical evaluation of spatial accuracy of a fusion imaging technique combining previously acquired computed tomography and real-time ultrasound for imaging of liver metastases. Cardiovasc Interv Radiol. 2011;34(2):338–44.CrossRefGoogle Scholar
- 19.Inyoung S, Hynchal R, Hyo KL, Young-Sun K, Dongil C. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol. 2009;19:2630–40.CrossRefGoogle Scholar
- 20.Farouil G, Deschamps F, Hakime A, de Baere T. Coil-assisted RFA of poorly visible liver tumors: effectiveness and risk factors of local tumor progression. Cardiovasc Interv Radiol. 2014;37(3):716–22.Google Scholar
- 21.Wang X, Sofocleous CT, Erinjeri JP, Petre EN, Gonen M, Do KG, Brown KT, Covey AM, Brody LA, Alago W, Thornton RH, Kemeny NE, Solomon SB. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Interv Radiol. 2013;36(1):166–75.CrossRefGoogle Scholar
- 30.Kim PN, Choi D, Rhim H, Rha SE, Hong HP, Lee J, et al. Planning ultrasound for percutaneous radiofrequency ablation to treat small (</=3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visibility. J Vasc Interv Radiol. 2012;23(5):627–34.CrossRefPubMedGoogle Scholar